Net Cash Provided by (Used in) Financing Activities of Vitro Biopharma, Inc. from 31 Oct 2010 to 31 Jan 2026

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Vitro Biopharma, Inc. quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Oct 2010 to 31 Jan 2026.
  • Vitro Biopharma, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Jan 2026 was $997,294.
  • Vitro Biopharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2025 was $2,642,920, a 29% decline from 2024.
  • Vitro Biopharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $3,713,168, a 144% increase from 2023.
  • Vitro Biopharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $1,524,483.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Vitro Biopharma, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $997,294 +$1,026,520 01 Nov 2025 31 Jan 2026 10-Q 16 Mar 2026 2026 Q1
Q4 2024 $29,226 -$3,012,705 -101% 01 Nov 2024 31 Jan 2025 10-Q 16 Mar 2026 2026 Q1
Q4 2023 $2,983,479 +$2,593,770 +666% 01 Nov 2023 31 Jan 2024 10-Q 20 Mar 2025 2025 Q1
Q4 2022 $389,709 +$770,935 01 Nov 2022 31 Jan 2023 10-Q 14 Mar 2024 2024 Q1
Q4 2021 $381,226 01 Nov 2021 31 Jan 2022 10-Q 14 Mar 2023 2023 Q1
Q4 2014 $26,635 -$17,223 -39% 01 Nov 2014 31 Jan 2015 10-Q 24 Mar 2015 2015 Q1
Q4 2013 $43,858 -$7,856 -15% 01 Nov 2013 31 Jan 2014 10-Q 24 Mar 2015 2015 Q1
Q4 2012 $51,714 -$5,232 -9.2% 01 Nov 2012 31 Jan 2013 10-Q 21 Mar 2013 2013 Q1
Q4 2011 $56,946 +$3,533 +6.6% 01 Nov 2011 31 Jan 2012 10-Q 21 Mar 2013 2013 Q1
Q4 2010 $53,413 01 Nov 2010 31 Jan 2011 10-Q 21 Mar 2012 2012 Q1

Vitro Biopharma, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $2,642,920 -$1,070,248 -29% 01 Nov 2024 31 Oct 2025 10-K 13 Feb 2026 2025 FY
2024 $3,713,168 +$2,188,685 +144% 01 Nov 2023 31 Oct 2024 10-K 13 Feb 2026 2025 FY
2023 $1,524,483 +$2,633,195 01 Nov 2022 31 Oct 2023 10-K 28 Jan 2025 2024 FY
2022 $1,108,712 01 Nov 2021 31 Oct 2022 10-K 29 Jan 2024 2023 FY
2015 $114,742 -$8,469 -6.9% 01 Nov 2014 31 Oct 2015 10-K 22 Sep 2016 2015 FY
2014 $123,211 +$8,978 +7.9% 01 Nov 2013 31 Oct 2014 10-K 22 Sep 2016 2015 FY
2013 $114,233 -$24,690 -18% 01 Nov 2012 31 Oct 2013 10-K 13 Feb 2015 2014 FY
2012 $138,923 +$31,171 +29% 01 Nov 2011 31 Oct 2012 10-K 12 Feb 2014 2013 FY
2011 $107,752 -$48,040 -31% 01 Nov 2010 31 Oct 2011 10-K 12 Feb 2013 2012 FY
2010 $155,792 01 Nov 2009 31 Oct 2010 10-K/A 16 Feb 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.